Cytokinetics, Inc.
Cytokinetics Appoints New Chief Legal and Administrative Officer
Summary
Cytokinetics, Incorporated announced on November 13, 2025, the appointment of Jeffrey J. Hessekiel as its new Executive Vice President and Chief Legal and Administrative Officer, effective November 14, 2025. Mr. Hessekiel, 56, previously served as Executive Vice President and General Counsel of Exelixis, Inc. He will receive an annual base salary of $660,000, a signing bonus of $400,000, and an initial equity award with a grant date value of $5,800,000. His compensation will also include participation in the company's benefit and compensatory plans.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement